ASH 2021 | Phase II study of pre-, during-, and post-transplant ruxolitinib for patients with myelofibrosis

Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment option available for patients with myelofibrosis. Ruxolitinib, the first JAK inhibitor approved for use in myelofibrosis, is often continued off-label during and after transplantation due to the challenges associated with discontinuation. Gabriela Hobbs, MD, Massachusetts General Hospital, Boston, MA, discusses the interim results of a Phase II multi-center trial (NCT03427866) investigating the use of ruxolitinib given pre-, during-, and post-HSCT for patients with myelofibrosis. To date, 26 patients have been recruited, with 1-year graft versus host disease (GvHD)-free and relapse-free survival (GRFS) assessed as the primary endpoint. Patients treated on the study performed well, with progression-free and overall survival and GRFS results superior to historical observations. Additionally, GvHD rates were very low. Recruitment is ongoing and an in-depth analysis of the impact of baseline mutational status will be conducted. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.